News

Microbiotica announced that it has entered into a multi-year strategic collaboration with Genentech, a member of the Roche Group, to discover, develop and commercialise biomarkers,…
Read More...

Thermo Fisher Scientific Inc. officially opened its U.S. Precision Medicine Science Center (PMSC) in Cambridge, Mass. The Center offers access to advanced "omics" technologies and…
Read More...

Genentech announced that the U.S. Food and Drug Administration (FDA) has approved Rituxan (rituximab) for the treatment of adults with moderate to severe pemphigus vulgaris (PV), a…
Read More...

GE Healthcare will provide Xiangxue Pharmaceutical Co., Ltd. (XPH) with a FlexFactory for cell therapy, a semi-automated end-to-end manufacturing platform, to help scale up, digitize…
Read More...

How can digital trends be used purposefully in regards to the application of injection systems? That is the key question being addressed by Vetter’s Open Innovation Challenge. This new…
Read More...

Blueprint Medicines Corporation and CStone Pharmaceuticals announced an exclusive collaboration and license agreement for the development and commercialization of avapritinib, BLU-554…
Read More...

Celltrion made an announcement that it will launch Bio CDMO (Contract Development and Manufacturing) business, in a bid to pursue open innovation for development of new drugs, at the…
Read More...

Biogen announced that it has entered into an exclusive option agreement with TMS Co., Ltd. to acquire TMS-007 and backup compounds. The agreement includes an upfront payment of $4…
Read More...

Pfizer Inc. announced that the U.S. Food and Drug Administration accepted for filing and granted Priority Review designation to the company’s New Drug Application for talazoparib. The…
Read More...

Chimerix announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for brincidofovir for the treatment of smallpox. Chimerix has been working…
Read More...

Ironwood Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to olinciguat (IW-1701) for the treatment of patients with sickle…
Read More...

BlackThorn Therapeutics announced enrollment of the first healthy volunteers in a Phase 1 study of BTRX-335140, a kappa opioid receptor (KOR) antagonist that targets brain circuits that…
Read More...

Chugai Pharmaceutical announced that the U.S. Food and Drugs Administration (FDA) has accepted the supplemental Biologics License Application (sBLA) and granted Priority Review for…
Read More...

Hookipa Biotech AG and Gilead Science announced that they have entered into a research collaboration and license agreement that grants Gilead exclusive rights to Hookipa’s TheraT and…
Read More...

InflaRx, a biopharmaceutical company developing innovative therapeutics to treat life-threatening inflammatory diseases by targeting the complement system, a key component of the innate…
Read More...

Sensei Biotherapeutics announced the publication of data from the company’s multi-center Phase 1 clinical trial to assess safety and immunogenicity of SNS-301 (formerly PAN-301) in…
Read More...

Virpax Pharmaceuticals signed a technology license agreement with LipoCure to develop pain management products using its liposome drug delivery technology. The first investigational…
Read More...

Mylan and Biocon announced that the U.S. Food and Drug Administration (FDA) has approved Mylan's Fulphila (pegfilgrastim-jmbd), a biosimilar to Neulasta (pegfilgrastim), co-developed…
Read More...

Merck announced interim results from Cohort A of KEYNOTE-427, a Phase 2 trial evaluating KEYTRUDA, Merck’s anti-PD-1 therapy, as first-line treatment for advanced clear cell renal cell…
Read More...

Novartis announced positive results from the third Phase III trial of Kisqali (ribociclib) in advanced or metastatic breast cancer. MONALEESA-3 showed Kisqali plus fulvestrant…
Read More...